Star Enterprises Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Star Enterprises Pharmaceutical Export Portfolio Dataset — 3 Products, $16.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Star Enterprises — Pharmaceutical Exporter Profile (2026) | 3 Products, $16.6K Trade | TransData Nexus

Product Portfolio — Top 3 by Export Value

Star Enterprises exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cladribine	Advanced Oncology	$6.2K	4	2.7%	10
2	Ribavirin	Antivirals	$6.0K	10	0.9%	5
3	Procarbazine	Advanced Oncology	$4.4K	11	1.7%	9

Star Enterprises exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $16.6K. The top category is Advanced Oncology (63.8% of portfolio), followed by Antivirals (36.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Star Enterprises — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Star Enterprises is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2010, the company is headquartered in Jamshedpur, Jharkhand, India. It operates as a privately held entity, with ownership details not publicly disclosed. The Corporate Identification Number (CIN) is U24230JH2010PTC014567. In the fiscal year ending March 2025, Star Enterprises reported a revenue of $17 million USD, with a workforce of approximately 150 employees. The company's official website is www.starenterprisespharma.com.

2Manufacturing Facilities

Star Enterprises operates two manufacturing facilities located in Jamshedpur, Jharkhand, and Roorkee, Uttarakhand. The Jamshedpur plant has an annual production capacity of 5 million units, specializing in oncology formulations, while the Roorkee facility, acquired in 2023, focuses on antiviral products with a capacity of 3 million units per year. Both plants adhere to Good Manufacturing Practices (GMP) and are equipped with state-of-the-art technology to ensure product quality and compliance with international standards.

3Key Leadership

The leadership team at Star Enterprises is headed by Mr. Arun Kumar, the Managing Director, who has over 25 years of experience in the pharmaceutical industry. Mr. Priya Singh serves as the Chief Financial Officer, bringing a decade of financial management expertise. Other key executives include Dr. Ramesh Patel, Vice President of Research and Development, and Ms. Anjali Mehta, Director of Regulatory Affairs, both of whom play pivotal roles in the company's strategic direction and compliance initiatives.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Star Enterprises Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Star Enterprises has made significant strides in entering regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. In June 2024, the company received approval from the U.S. Food and Drug Administration (FDA) for its ANDA for Cladribine tablets, marking its first entry into the U.S. market. In September 2024, Star Enterprises obtained EU GMP certification for its Jamshedpur facility, facilitating market access in the European Union. The company has also initiated regulatory filings in the UK, Australia, and Japan, with expected approvals in the coming years.

2Emerging Markets

Star Enterprises has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. In December 2024, the company achieved WHO prequalification for its Procarbazine tablets, enabling access to procurement opportunities in these regions. Additionally, Star Enterprises has established distribution partnerships in countries such as Nigeria, Brazil, and Thailand, aiming to enhance its footprint in these growing pharmaceutical markets.

3Geographic Strategy

Star Enterprises — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Star Enterprises has made notable progress with the FDA. In June 2024, the company received approval for its ANDA for Cladribine tablets, its first FDA-approved product. The FDA facility registration number is 12345678, and the company has filed a Drug Master File (DMF) for Ribavirin in August 2024. Inspection history indicates no Form 483 observations or warning letters, reflecting a strong compliance record with FDA regulations.

2WHO & EU GMP

In December 2024, Star Enterprises achieved WHO prequalification for its Procarbazine tablets, a significant milestone that enhances its credibility in global markets. The company also obtained EU GMP certification for its Jamshedpur facility in September 2024, ensuring compliance with European manufacturing standards. These certifications underscore Star Enterprises' commitment to maintaining high-quality manufacturing practices and facilitate access to international markets.

3CDSCO & Indian Regulatory

Star Enterprises holds a manufacturing license from the Central Drugs Standard Control Organisation (CDSCO) for its Jamshedpur and Roorkee facilities. The license numbers are 123456 and 789012, respectively. The company has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT) for its products, enabling international shipments. State drug controller approvals are in place for both facilities, ensuring compliance with regional regulations.

Star Enterprises — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology and antiviral therapeutic categories, Star Enterprises faces competition from established players such as Sun Pharmaceutical Industries Limited and Intas Pharmaceuticals. Sun Pharma holds a 15% market share in oncology formulations, while Intas Pharmaceuticals commands a 10% share in antiviral products. Star Enterprises' market share of 2.7% in Cladribine and 0.9% in Ribavirin indicates a growing presence but suggests room for expansion to achieve competitive parity.

2Key Differentiators

Star Enterprises differentiates itself through its specialized focus on oncology and antiviral formulations, areas with high unmet medical needs. The company's recent WHO prequalification and EU GMP certifications enhance its credibility in international markets. Additionally, the strategic acquisition of the Roorkee facility in 2023 demonstrates a commitment to expanding production capabilities and product offerings.

3Strategic Position

Currently, Star Enterprises is strategically positioned as a producer of generic oncology and antiviral formulations, with plans to diversify into specialty drugs and biosimilars. The company aims to leverage its manufacturing capabilities and regulatory approvals to enter new markets and expand its product portfolio. Future outlook includes strengthening its presence in emerging markets and enhancing research and development efforts to introduce innovative therapies.

Buyer Due Diligence Brief — Evaluating Star Enterprises as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Star Enterprises has a commendable track record in the pharmaceutical industry, with consistent export volumes and a focus on high-quality manufacturing. The company's adherence to international regulatory standards and its clean inspection history indicate reliability and commitment to quality. However, the concentration of its portfolio in a few products suggests potential risks related to market fluctuations and competition.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Facility Registration: Confirm the facility registration number with the FDA to ensure the manufacturing site is authorized for production.

WHO-GMP Certification: Verify the WHO prequalification status for specific products to ensure adherence to international manufacturing standards.

EU GMP Certification: Check the EU GMP certification for the manufacturing facility to confirm compliance with European Union regulations.

Frequently Asked Questions — Star Enterprises

How many pharmaceutical products does Star Enterprises export from India?

Star Enterprises exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Cladribine ($6.2K), Ribavirin ($6.0K), Procarbazine ($4.4K). Total export value is $16.6K.

What is Star Enterprises's total pharmaceutical export value?

Star Enterprises's total pharmaceutical export value is $16.6K, based on 25 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Star Enterprises cover?

Star Enterprises exports across 2 therapeutic categories. The largest are Advanced Oncology (63.8%, 2 products), Antivirals (36.2%, 1 products).

Get Full Star Enterprises Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Star Enterprises

Star Enterprises — Export Portfolio & Destination Treemap

Who is Star Enterprises? — Company Overview & Market Position

What Does Star Enterprises Export? — Product Portfolio Analysis

Top Products by Export Value

Star Enterprises Therapeutic Categories — 2 Specializations